Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis

Zhaojun Shen¹, Hui Luo¹, Saisai Li¹, Bo Sheng¹, Menghuang Zhao¹, Haiyan Zhu¹ and Xueqiong Zhu¹

¹Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China

Correspondence to: Xueqiong Zhu, email: zjwzzxq@163.com
Haiyan Zhu, email: zhuhaiyandoc@sina.com

Keywords: epithelial ovarian cancer, estrogen receptor, prognosis, meta-analysis

Received: March 24, 2017  Accepted: April 26, 2017  Published: May 29, 2017

Copyright: Shen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Objective: Accumulated studies have investigated the prognostic significance of estrogen receptor expression in epithelial ovarian cancer, but results remain controversial. The aim of this study was to perform a meta-analysis to clarify the prognostic value of estrogen receptor expression in epithelial ovarian cancer.

Methods: A systematic search was performed in PUBMED, EMBASE, and COCHRANE databases to identify relevant studies up to December 2016. The pooled hazard rates (HR) with 95% confidence intervals (CIs) for overall survival and time to tumor progression were calculated and then weighted and pooled in this meta-analysis with a random-effect model.

Results: Thirty-five studies with a total of 5824 patients were included. In brief, the expression of estrogen receptor was associated with an improved overall survival (HR = 0.86, 95% CI = 0.76-0.97), whereas there was no significant difference between estrogen receptor and time to tumor progression among epithelial ovarian cancer patients. Subgroup analysis revealed that estrogen receptor expression was significantly correlated with overall survival in different subgroups, such as in unclassified epithelial ovarian cancer (HR= 0.80, 95% CI = 0.66-0.95), studies using immunohistochemistry detection method (HR= 0.85, 95% CI = 0.73-1.00), European population (HR= 0.75, 95% CI = 0.60-0.94) and estrogen receptor α subtype (HR= 0.78, 95% CI = 0.62-0.98).

Conclusions: Estrogen receptor, especially estrogen receptor α, was associated with an improved overall survival in epithelial ovarian cancer. Estrogen receptor expression may be a promising prognostic factor in epithelial ovarian cancer patients.

INTRODUCTION

Ovarian cancer is the second most common and leading lethal gynecological cancer [1]. About 90% of these subtypes are epithelial ovarian cancer (EOC). In the United States, approximately 22,440 new cases and 14,080 deaths from ovarian cancer were estimated in 2017 [1]. Despite considerable efforts have been made to improve surgical techniques and meticulously designed chemotherapy regimens, the 5-year survival rate remains 10% ~ 30% [2–4]. The high rate of lethality and poor rate of survival are primarily due to late detection and rapid progression [2–4]. For these reasons, identifying reliable predictive biomarkers for prognosis and developing novel therapeutic strategies are urgently needed.

Estrogen and estrogen receptor (ER) have been well documented to be associated with ovarian cancer [5]. Estrogens promote physiological actions, such as cell
survival and proliferation, after binding to their estrogen receptors (ERs) subtypes (ER α and ER β) [6]. The frequency of ER expression in human epithelial ovarian carcinoma has been reported varying in the range of 43%–81% immunohistochemically [7, 8]. In ER-positive human ovarian cancers, estrogen promoted cancer cell growth in vitro [9]. Conversely, anti-estrogens inhibited cell growth both in vitro and in vivo [10].

Given its important role in ovary carcinogenesis, multiple studies have investigated the relationship between estrogen receptor expression and epithelial ovarian cancer clinical outcomes, with contradictory findings [9–13]. While researches by Bizzi et al [11] and Yang et al [12] reported that ER expression predicted an improved outcomes in epithelial ovarian cancer, Liew et al [4] reported that the expression of ER had no effect on clinical outcomes among epithelial ovarian cancer patients. On the contrary, Khandakar et al [14] supported a negative relationship between ER expression and overall survival of epithelial ovarian cancer. Thus, in epithelial ovarian cancers, the prognostic significance of estrogen receptor remains unclear.

A similar situation, the prognostic value of ER α and ER β in epithelial ovarian cancer patients was also controversial. While the expression of ER α was shown to predict a better prognosis in the research by de Toledo et al [15], Zamagni et al [16] reported a positive ER α status was associated with a negative prognosis of epithelial ovarian cancer in their study. The prognostic value of ER β in epithelial ovarian cancer patients also was controversial [3, 6]. Therefore, it was necessary to evaluate the association between ER expression and the survival of women with epithelial ovarian cancer by a meta-analysis.

In this study, we performed a meta-analysis to evaluate the prognostic value of ER and its two subtypes (ER α and ER β) in patients with epithelial ovarian cancer, aiming to provide more strategies for follow-up and targeted regimens.

RESULTS

Literature search results

Initially, 726 relevant citations were retrieved in PUBMED, EMBASE, and COCHRANE databases. After reviewing titles and abstracts, 464 studies were eliminated for clearly irrelevant. Among the remaining 262 studies, 6 studies were further excluded because they were not written in English; 136 articles were excluded because of conference abstracts or other studies; 46 studies were irrelevant to ovarian cancer and prognosis; 39 studies were excluded due to insufficient data for quantitative analysis. Ultimately, 35 studies [3–8, 11–39] with a total of 5824 patients were included in this meta-analysis. Details of the study selection process were presented in Figure 1.

Characteristics of included studies

In this meta-analysis, while 35 studies described the correlation between overall survival (OS) and ER expression and 18 trials involved in disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival (RFS). Since DFS, PFS and RFS were similar in meaning, these three outcome endpoints were combined as an unified prognostic parameter, time to tumor progression (TTP) [40]. All of the selected studies focused on epithelial ovarian cancer, in which only 12 studies concentrated on serous ovarian cancer and the remaining 23 studies involved in various subtypes of epithelial ovarian cancers (unclassified epithelial ovarian cancer). Among 35 studies, 11 reporters evaluated the association between ER α and epithelial ovarian cancer clinical outcome and 8 studies investigated the prognostic value of ER β among epithelial ovarian cancer patients.

As for the region, 19 studies were performed in Europe, 7 studies in North America, 5 studies in Asia, 2 studies in South America, 1 study in Oceania, and 1 study was conducted across regions. With respect to detection method, 20 studies used immunohistochemical staining for estrogen receptor assessment, 2 studies used polymerase chain reaction, and the other 4 studies used dextran-coated charcoal method.

The quality of included studies was assessed by the Newcastle-Ottawa Scale (NOS) and the scores of all studies were more than six, suggesting a high methodological quality across all studies. Detailed characteristics of eligible studies were presented in Table 1.

Quality assessment of relationship between ER expression and OS

A total of 35 studies were included to evaluate the association between ER expression and OS of epithelial ovarian cancer. The pooled data of 35 datasets showed that ER expression was significantly associated with an improved OS of epithelial ovarian cancer (HR = 0.86, 95% CI = 0.76-0.97). A moderate heterogeneity was observed (I² = 70.2%, P = 0.00), therefore a random-effect model was used to calculate the pooled HR and 95% CI (Figure 2). Moreover, according to various confounding factors, subgroup analysis was performed to explore the potential source of the heterogeneity among these studies (Figure 3, Table 2).

In the stratified analysis by pathological type, ER expression was associated with a better OS (HR = 0.80, 95% CI = 0.66-0.95) in unclassified epithelial ovarian cancer. Nevertheless, ER expression had no value on overall survival of serous ovarian cancer (HR =0.90, 95% CI = 0.75-1.08).

Subgroup analysis by regions revealed that ER expression was a favorable indicator of OS in South
American group (HR = 0.52, 95% CI = 0.32-0.85), Oceanian group (HR = 0.51, 95% CI = 0.34-0.77) and European group (HR = 0.75, 95% CI = 0.60-0.94). Nevertheless, ER positivity was irrelevant to OS of ovarian cancer in Asian population, North American group and the across regions group.

Subgroup analysis based on detection methods for ER expression included immunological histological chemistry (IHC), polymerase chain reaction (PCR) and dextran-coated charcoal method (DCCM). The results suggested that ER expression was related to a favorable OS of epithelial ovarian cancer using IHC for ER detection (HR = 0.85, 95% CI = 0.73-1.00). Nevertheless, when using PCR or DCCM to detect ER expression, no significant correlations were found between ER and OS of epithelial ovarian cancer.

With regard to subtypes of ER α and ER β in epithelial ovarian cancer, as shown in Figure 3, ER α expression (HR = 0.78, 95% CI = 0.62-0.98) had a certain value in predicting a favorable OS, whereas the expression of ER β (HR = 1.21, 95% CI 0.85-1.74) was irrelevant with OS of epithelial ovarian cancer patients.

**Quality assessment of relationship between ER expression and TTP**

Intriguingly, as shown in Figure 4, no significant correlation was observed between ER expression and TTP among epithelial ovarian cancer patients (HR = 1.04, 95% CI = 0.95-1.13). Similarly, neither ER α (HR = 0.99, 95% CI = 0.86-1.15) nor ER β (HR = 1.28, 95% CI = 0.85-1.91) showed effect on TTP of ovarian cancer (Figure 5). Significant heterogeneity was shown among these studies ($I^2 = 42\%, P = 0.032$). Thus, a random-effect model was used for statistical analysis.

We further performed subgroup meta-analysis according to different regions, pathological types, ER detection methods, as expected, ER had no association with TTP of ovarian cancer in all subgroups (Figure 5, Table 3).

---

**Figure 1: Flow of study identification, inclusion, and exclusion.**
Table 1: Characteristics of eligible studies

| Study & year | Country | Region | Sample size(n) | Age (year) | Follow-up (months) | Way of evaluation | Pathological type | Method for data collection | Outcomes | HR (95%CI) | NOS score |
|-------------|---------|--------|----------------|-----------|------------------|------------------|----------------|--------------------------|-----------|-----------|-----------|
| Jönsson 2015[3] | Sweden | Europe | 118 | Mean(range) 58(26-83) | 60 | IHC | EOC | Directly | OS | 1.13 (0.78-1.64) | 6 |
| Jönsson 2015[3] | Sweden | Europe | 118 | Mean(range) 58(26-83) | 60 | IHC | EOC | Directly | PFS | 1.20 (0.77-1.63) | 7 |
| Liew 2015[4] | China | Asia | 108 | Median 53 | Median 41 | IHC | EOC | Directly | OS | 1.08 (0.85-1.36) | 7 |
| Liew 2015[4] | China | Asia | 108 | Median 53 | Median 41 | IHC | EOC | Directly | DFS | 1.025 (0.81-1.30) | 7 |
| de Toledo 2014[15] | Brazil | South America | 152 | Mean(SD) 55.2(12.3) | Mean 43.6 | IHC | EOC (serous) | Indirectly | OS | 0.46 (0.22-0.95) | 8 |
| de Toledo 2014[15] | Brazil | South America | 152 | Mean(SD) 55.2(12.3) | Mean 43.6 | IHC | EOC (serous) | Directly | DFS | 0.35 (0.03-0.68) | 7 |
| Tkalia 2014[5] | Ukraine | Europe | 232 | Mean(SD) 51.7(0.8) | Mean(SD) 39.5(1.7) | IHC | EOC (serous) | Indirectly | OS | 0.89 (0.64-1.23) | 6 |
| Tkalia 2014[5] | Ukraine | Europe | 232 | Mean(SD) 51.7(0.8) | Mean(SD) 39.5(1.7) | IHC | EOC (serous) | Indirectly | RFS | 0.95 (0.68-1.33) | 8 |
| Ciucci 2014[6] | Italy | Europe | 56 | Median(range) 54 (33–79) | Mean(range) 47(9-162) | IHC | EOC (serous) | Indirectly | OS | 2.8 (1.3-5.7) | 8 |
| Ciucci 2014[6] | Italy | Europe | 56 | Median(range) 54 (33–79) | Mean(range) 47(9-162) | IHC | EOC (serous) | Indirectly | DFS | 1.6 (0.9-2.9) | 7 |
| Lenhard 2012[22] | Germany | Europe | 155 | Mean(range) 59 (21–88) | Median 146.4 | IHC | EOC | Directly | OS | 0.86 (0.52-1.43) | 8 |
| Høgdall 2007[8] | Denmark | Europe | 580 | NA | 120 | IHC | EOC | Directly | OS | 0.8 (0.63-0.99) | 6 |
| García-Velasco 2008[13] | Spain | Europe | 72 | Median(range) 57(28-82) | Median(range) 33(1-193) | IHC | EOC | Directly | OS | 0.23 (0.14-0.55) | 7 |
| García-Velasco 2008[13] | Spain | Europe | 72 | Median(range) 57(28-82) | Median(range) 33(1-193) | IHC | EOC | Directly | PFS | 1.4 (0.73-2.93) | 7 |
| Bizzi 1998[11] | Italy | Europe | 97 | Median(range) 58(24-81) | 36 | DCCM | EOC | Directly | OS | 0.4 (0.23-0.71) | 7 |
| Scambia 1995[26] | Italy | Europe | 117 | Range (40-60) | Median(range) 19(2-110) | DCCM | EOC | Indirectly | OS | 0.92 (0.52-1.61) | 8 |
| Scambia 1995[26] | Italy | Europe | 117 | Range (40-60) | Median(range) 19(2-110) | DCCM | EOC | Indirectly | PFS | 0.98 (0.58-1.66) | 8 |

(Continued)
| Study & year | Country | Region | Sample size(n) | Age (year) | Follow-up (months) | Way of evaluation | Pathological type | Method for data collection | Outcomes | HR (95%CI) | NOS score |
|-------------|---------|--------|----------------|-----------|-------------------|------------------|-----------------|------------------------|-----------|------------|----------|
| Kieback 1993[27] | USA | North America | 42 | NA | 96 | IHC | EOC (serous) | Indirectly | OS | 0.72 (0.34-1.51) | 7 |
| Geisler 1996[28] | USA | North America | 96 | Mean(range) 59(38-88) | 60 | DCCM | EOC (serous) | Indirectly | OS | 0.87 (0.51-1.48) | 7 |
| Athanassiadou 1998[29] | Greece | Europe | 100 | Mean(SD) 51.56(10.2) | 28.5 | DCCM | EOC (serous) | Indirectly | OS | 0.89 (0.52-1.53) | 6 |
| Lee 2005[30] | USA | North America | 322 | Mean(range) 58.3(20-86) | Mean(range) 64(1-120) | IHC | EOC | Directly | OS | 1.2 (0.8-1.8) | 6 |
| Athanassiadou 1998[29] | Greece | Europe | 100 | Mean(SD) 51.56(10.2) | 28.5 | DCCM | EOC (serous) | Indirectly | OS | 0.57 (0.3-1.09) | 6 |
| Yang 2008[12] | China | Asia | 86 | Median(range) 34.2(17-40) | 60 | IHC | EOC | Directly | OS | 0.49 (0.19-1.25) | 8 |
| Buchynska 2009[32] | Ukraine | Europe | 81 | Mean(SD) 46.6(2.4) | 60 | IHC | EOC (serous) | Indirectly | OS | 0.28 (0.14-0.54) | 8 |
| Burges 2010[17] | Germany | Europe | 100 | Mean(range) 60.35(33,12-89.2) | 160 | IHC | EOC (serous) | Directly | OS | 0.5 (0.36-0.84) | 7 |
| Darb-Esfahani 2009[34] | Germany | Europe | 139 | Mean(range) 57(33-81) | Mean(range) 38(2-118) | IHC | EOC | Directly | OS | 0.72 (0.26-1.94) | 7 |
| Zamagni 2009[16] | Italy | Europe | 35 | Mean(range) 67(43-78) | 42 | PCR | EOC | Indirectly | OS | 0.21 (0.05-0.92) | 6 |
| Liu 2009[35] | USA | North America | 127 | NA | 100 | IHC | EOC (serous) | Indirectly | OS | 0.65 (0.41-1.04) | 8 |
| Alonso 2009[36] | Spain | Europe | 62 | Median 56 | Median 27 | IHC | EOC | Indirectly | OS | 9.95 (1.9-51) | 8 |
| Alonso 2009[36] | Spain | Europe | 62 | Median 56 | Median 27 | IHC | EOC | Indirectly | PFS | 1.1 (0.46-2.65) | 7 |
| Liu 2010[37] | China | Asia | 116 | Median(range) 49(30-76) | Median(range) 43(5-93) | IHC | EOC | Directly | OS | 1.18 (0.48-2.88) | 7 |
| Liu 2010[37] | China | Asia | 116 | Median(range) 49(30-76) | Median(range) 43(5-93) | IHC | EOC | Directly | PFS | 1.16 (0.47-2.86) | 7 |

(Continued)
| Study & year | Country | Region | Sample size(n) | Age (year) | Follow-up (months) | Way of evaluation | Pathological type | Method for data collection | Outcomes | HR (95%CI) | NOS |
|-------------|---------|--------|----------------|------------|-------------------|------------------|------------------|-------------------------|----------|-----------|-----|
| Schlumbrecht 2011[25] | USA | North America | 83 | Mean(range): 62.6(34.5-85.9) | Median(range): 38.7(0.5-67.8) | PCR | EOC (serous) | Directly | OS | 0.99 (0.94-1.03) | 8 |
| Schlumbrecht 2011[25] | USA | North America | 83 | Mean(range): 62.6(34.5-85.9) | Median(range): 38.7(0.5-67.8) | PCR | EOC (serous) | Directly | RFS | 1.02 (0.99-1.04) | 8 |
| Halon 2011[18] | Poland | Europe | 43 | Mean: 62.6, Median: 38.7 | 60 | IHC | EOC | Indirectly | OS | 0.21 (0.05-0.85) | 6 |
| Halon 2011[18] | Poland | Europe | 43 | Mean: 62.6, Median: 38.7 | 60 | IHC | EOC | Indirectly | PFS | 0.47 (0.24-0.95) | 6 |
| De Stefano 2011[38] | Italy | Europe | 58 | Median(range): 54(33-79) | Median(range): 35(9-127) | IHC | EOC (serous) | Directly | OS | 0.86 (0.52-1.4) | 7 |
| Kolkova 2012[39] | Sweden | Europe | 150 | NA | 120 | IHC | EOC | Indirectly | OS | 1.08 (0.73-1.6) | 7 |
| van Kruchten 2015[19] | Netherlands | Europe | 121 | Median(range): 61(30-84) | 45 | IHC | EOC | Directly | OS | 1.37 (0.92-2.02) | 7 |
| van Kruchten 2015[19] | Netherlands | Europe | 121 | Median(range): 61(30-84) | 45 | IHC | EOC | Directly | PFS | 1.24 (0.85-1.64) | 7 |
| Khandakar 2014[14] | India | Asia | 62 | Mean: 55 | 70 | IHC | EOC (serous) | Indirectly | OS | 1.95 (1-3.81) | 8 |
| Matsuo 2014[20] | USA | North America | 121 | Mean(SD): 62.6(10.6) | 96 | IHC | EOC (serous) | Directly | OS | 1.76 (0.7-4.4) | 8 |
| Matsuo 2014[20] | USA | North America | 121 | Mean(SD): 62.6(10.6) | 96 | IHC | EOC (serous) | Directly | PFS | 2.03 (1.01-4.06) | 8 |
| Battista 2014[21] | Germany | Europe | 108 | Mean(range): 61.7(11.4) | Median(range): 43.3(11.4-8) | IHC | EOC | Directly | OS | 0.6 (0.28-1.26) | 7 |
| Battista 2014[21] | Germany | Europe | 108 | Mean(range): 61.7(11.4) | Median(range): 43.3(11.4-8) | IHC | EOC | Directly | DFS | 0.9 (0.52-1.69) | 7 |
| Sieh 2013[7] | USA | Across regions | 1691 | Mean(range): 60.9(11.4) | Mean(range): 49.2(33.6) | IHC | EOC (serous) | Directly | OS | 1 (0.89-1.14) | 7 |
| Sieh 2013[7] | USA | Across regions | 1691 | Mean(range): 60.9(11.4) | Mean(range): 49.2(33.6) | IHC | EOC (serous) | Directly | DFS | 1.06 (0.93-1.2) | 6 |
| Fujiwara 2012[23] | Japan | Asia | 162 | Mean(range): 54.1(12.5) | 62.4 | IHC | EOC | Indirectly | OS | 1.31 (0.95-1.81) | 6 |
| Aust 2012[24] | Austria | Europe | 208 | Median(range): 56(18-85) | Median 51 | IHC | EOC | Directly | OS | 0.51 (0.34-0.77) | 6 |
| Aust 2012[24] | Austria | Europe | 208 | Median(range): 56(18-85) | Median 51 | IHC | EOC | Directly | PFS | 0.8 (0.58-1.11) | 8 |

EOC: epithelial ovarian cancer; IHC: immunological histological chemistry; PCR: polymerase chain reaction; DCCM: dextran-coated charcoal method; OS: overall survival; PFS: progression-free survival; DFS: disease-free survival; RFS: recurrence-free survival.
Figure 2: Forest plot of HR and 95% CI in the meta-analysis of the association between estrogen receptor expression and overall survival of ovarian cancer patients. Summary of 35 studies, the results showed estrogen receptor was associated with a favorable overall survival of ovarian cancer using random effects model. The % weight was computed automatically by the Stata software.

Figure 3: Subgroup analysis of the association between estrogen receptor expression and overall survival of ovarian cancer.
Publication bias

Funnel plots analyses were graphically symmetric, as indicated by Begg’s test, there was no significant publication bias for both OS (Begg’s test, \( P = 0.173 \)) and TTP (Begg’s test, \( P = 0.649 \)) among the included studies. (Figure 6).

Sensitivity analysis

As shown in Figure 7, the leave-one-out method was applied to confirm the stability of the results. Eligible studies were sequentially excluded one by one to evaluate the stability of the obtained conclusions from the remaining data. The statistical significance of the results about OS and TTP was not altered when any single study was omitted. This analysis indicated that the results from this present meta-analysis were reliable.

DISCUSSION

In the current meta-analysis, we investigated the correlation between ER expression and epithelial ovarian cancer prognosis, and demonstrated that the expression of ER, especially ER \( \alpha \), was a positive predictor of overall survival among epithelial ovarian cancer patients. Nevertheless, ER expression showed no effect on TTP of epithelial ovarian cancer. This study included 35 published articles with a total number of 5824 patients. To our knowledge, this is the most comprehensive assessment of the association between ER expression and epithelial ovarian cancer prognosis to date. Our result is not consistent with the only previous study to explore the prognostic role of ER in ovarian cancer in 2013 [41]. Zhao et al [41] investigated 2784 ovarian cancer patients and found ER failed to predict clinical outcomes of ovarian cancer patients. This can be partly attributed to small sample size. Furthermore, the previous study did not perform subgroup meta-analysis although there was an obvious heterogeneity.

Regarding the histopathological types, our results showed that the expression of ER was related to neither OS nor TTP in serous type of cancers. Epithelial ovarian cancers mainly consist of five histological subtypes: high-grade serous

### Table 2: Subgroup analysis of the association between estrogen receptor expression and overall survival of ovarian cancer

| Subgroup               | No. of studies | HR (95% CI)        | Heterogeneity |
|------------------------|----------------|-------------------|---------------|
|                        |                |                   | \( P \) value | \( I^2 \) (%) |
| Region                 |                |                   |               |               |
| Europe                 | 19             | 0.75(0.60,0.94)   | 0             | 70.6          |
| South America          | 2              | 0.52(0.32,0.85)   | 0.645         | 0             |
| Oceania                | 1              | 0.51(0.34,0.77)   | -             | -             |
| Asia                   | 5              | 1.16(0.90,1.49)   | 0.228         | 29.1          |
| North America          | 7              | 0.96(0.89,1.08)   | 0.379         | 6.3           |
| Across regions         | 1              | 1.01(0.86,1.18)   | -             | -             |
| Pathological type      |                |                   |               |               |
| Serous OC              | 12             | 0.90(0.75,1.08)   | 0             | 68.1          |
| Unclassified OC        | 23             | 0.80(0.66,0.95)   | 0             | 65.8          |
| ER detection method    |                |                   |               |               |
| IHC                    | 29             | 0.85(0.73,1.00)   | 0             | 67.3          |
| PCR                    | 2              | 0.54(0.12,2.39)   | 0.037         | 77            |
| DCCM                   | 4              | 0.72(0.49,1.07)   | 0.127         | 47.4          |
| Subtype of ER          |                |                   |               |               |
| ER \( \alpha \)        | 11             | 0.78(0.62,0.98)   | 0.005         | 60.7          |
| ER \( \beta \)         | 8              | 1.21(0.85,1.74)   | 0.017         | 59            |

No.: number; HR: hazard ratio; CI: confidence interval; IHC: immunological histological chemistry; PCR: polymerase chain reaction; DCCM: dextran-coated charcoal method.
Figure 4: Forest plot of HR and 95% CI in the meta-analysis of the association between estrogen receptor expression and time to tumor progression of ovarian cancer patients. Summary of 18 studies, the results showed estrogen receptor was not associated with time to tumor progression of ovarian cancer using random effects model.

Figure 5: Subgroup analysis of the association between estrogen receptor expression and time to tumor progression of ovarian cancer.
Table 3: Subgroup analysis of the association between estrogen receptor expression and time to tumor progression of ovarian cancer

| Subgroup                   | No. of studies | HR (95%CI)       | Heterogeneity |
|----------------------------|----------------|------------------|---------------|
|                            |                |                  | P value       | I² (%)        |
| Region                     |                |                  |               |               |
| Europe                     | 11             | 1.05 (0.88,1.26) | 0.048         | 45.8          |
| South America              | 1              | 0.35 (0.07,1.67) | -             | -             |
| Oceania                    | 1              | 0.80 (0.58,1.11) | -             | -             |
| Asia                       | 2              | 1.03 (0.82,1.30) | 0.795         | 0             |
| North America              | 2              | 1.31 (0.69,2.52) | 0.053         | 73.4          |
| Across regions             | 1              | 1.05 (0.89,1.24) | -             | -             |
| Pathological type          |                |                  |               |               |
| Serous OC                  | 6              | 1.07 (0.89,1.30) | 0.012         | 65.8          |
| Unclassified OC            | 12             | 1.04 (0.93,1.17) | 0.27          | 17.7          |
| ER detection method        |                |                  |               |               |
| IHC                        | 15             | 1.03 (0.87,1.21) | 0.022         | 47.1          |
| PCR                        | 2              | 1.05 (0.97,1.13) | 0.103         | 62.4          |
| DCCM                       | 1              | 0.99 (0.58,1.69) | -             | -             |
| Subtype of ER              |                |                  |               |               |
| ER α                       | 7              | 0.99 (0.86,1.15) | 0.002         | 70.9          |
| ER β                       | 4              | 1.28 (0.85,1.91) | 0.263         | 24.7          |

No.: number; HR: hazard ratio; CI: confidence interval; IHC: immunological histological chemistry; PCR: polymerase chain reaction; DCCM: dextran-coated charcoal method.

Figure 6: (A) Begg's funnel plots for the studies involved in the meta-analysis of estrogen receptor expression and overall survival of ovarian cancer patients. (B) Begg's funnel plots for the studies involved in the meta-analysis of estrogen receptor expression and time to tumor progression of ovarian cancer patients. Visual inspection of the Begg's funnel plot did not indicate substantial asymmetry.
cancer, low-grade serous cancer, mucinous, endometrioid, and clear cell cancer [7]. It is now recognized that ovarian cancer subtypes have different etiologies and distinct clinical courses. The association of tumor biomarker expression with survival varies substantially across subtypes [7]. Indeed, the expression of ER differed markedly across ovarian subtypes. Sieh et al [7], in their study on 2933 ovarian cancer patients with various epithelial histology by IHC, reported that the expression of ER was much higher in serous carcinoma and endometrioid cancer than in mucinous carcinoma and clear cell carcinoma. Along similar lines, in another large cohort, ER positivity was much lower in the mucinous and clear cell subtype but endometrioid type had a similar ER positivity with serous carcinomas [8]. These results suggest that the role and its mechanisms of action of ER in ovary carcinogenesis across ovarian cancer subtypes. Therefore, we suggest that the expression of ER may be a prognostic biomarker in non-serous epithelial ovarian cancer rather than serous ovarian cancer. Further stratification analysis was needed to clarify the prognostic value of ER in each type of non-serous epithelial ovarian cancer.

With respect to source regions, ER expression was correlated with better clinical outcomes of epithelial ovarian patients in European group, South American group and Oceanian group but not in other groups. A probable explanation for these results is that certain genes exert different effects on cancer risk and prognosis across ethnic populations. It is well known that tumor estrogen receptor state differs by race in breast cancer. The proportion of ER-positive tumors was much higher among Non-Hispanic Whites population comparing to Non-Hispanic Black population [42].

Additionally, we studied deeply on the way of ER detection methods. We observed that a positive ER status was generally associated with an improved OS in epithelial ovarian cancer using IHC. Immunohistochemical examination of ER status has been used as a standard-of-care pathological evaluation to guide adjuvant endocrine therapy after surgery of breast cancer [43]. It is the main technology used to determine protein expression status in tissue and has been widely used in the morphological diagnosis of malignancy and contributes to decisions on prognosis. According to our results, we suggested that using immunohistochemistry to evaluate ER expression in postoperative ovarian cancer samples routinely may benefit the prognosis of epithelial ovarian cancer.

Estrogens exert their action through two estrogen receptors (ER α and ER β) [6]. ER α was a well-established biomarker predicting better outcomes in women with breast cancer in Han et al’s study [43]. Consistent with breast cancer, our study demonstrated that ER α predicted a favorable prognosis for ovarian cancer patients. Nevertheless, the expression of ER β was irrelevant with both OS and DFS/RFS/PFS of ovarian cancer patients. A potential mechanism responsible for these findings may be the distinct function of ERs subtypes in the carcinogenesis of the ovary. ER β receptor displays a high expression compared to ER α in normal ovarian epithelium, but this ratio is reversed in ovarian cancers [44].

There are several important implications in this meta-analysis. First, our study showed that ER expression was related to a better outcome of epithelial ovarian cancer, indicating ER may be a potential prognostic biomarker for patients with epithelial ovarian cancer. Second, we identified a subgroup of tumors with unfavorable outcome potentially in epithelial ovarian cancer. Finally, we emphasize the importance of evaluating ER expression by immunohistochemistry in epithelial ovarian cancer paraffin block as a valuable biomarker for prognostic assessment.

Some limitations also existed in this analysis. First, we could only extract summarized population-level data rather than individual patient-level data from the literature. Second, the HR of some studies was indirectly extracted from growth curve, which was less reliable than the data.
directly obtained from primary literatures. In addition, the heterogeneity across studies could not be eliminated completely, which could result in bias of the outcome. Finally, small studies with negative or null results may not be published, which can cause publication bias. Therefore, further investigations are needed to address the above limitations.

In conclusion, this meta-analysis demonstrates that the expression of ER, especially ER α, is associated with an improved OS, which suggests that ER might be a potential biomarker for prognostic prediction in epithelial ovarian cancer. Additionally, evaluating ER expression by immunohistochemistry in ovarian cancer paraffin is an economical and effective method for predicting ovarian cancer clinical outcomes.

MATERIALS AND METHODS

Search strategy

An electronic search of the following databases for relevant studies was performed: PUBMED, EMBASE, and COCHRANE. The research started from November 1980 to December 2016. The search items included “Estrogen receptor” or ER and “Ovarian Neoplasms” or “Ovarian Neoplasm” or “Ovary Neoplasms” or “Ovary Neoplasm” or “Ovary Cancer” or “Ovary Cancers” or “Ovarian Cancer” or “Ovarian Cancers” or “Cancer of Ovary” or “Cancer of the Ovary” and “Prognosis” or “prognostic” or “Survival” or “outcome”. The search was limited to English language articles, but no limitation on regions of publications. Reference lists of all relevant articles were manually screened to ensure the accuracy of the literature search.

Selection criteria and quality assessment

Studies had to meet the following inclusion criteria: (1) detection of ER expression in primary ovarian cancer tissue; (2) outcomes were survival related, such as overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), or recurrence-free survival (RFS); (3) original article was written in English.

Exclusion criteria were as follows: (1) review articles, experimental studies, letters, comments, meta-analysis, conference articles or case reports; (2) non-English studies; (3) absence of key information such as hazards ratio (HR), 95% confidence interval (CI) and sample size. Two independent reviewers (ZJS and HL) evaluated eligibility of studies according to the above criteria. The information collected would be repeatedly examined by each other. Disagreements were resolved by discussion.

The Newcastle-Ottawa quality assessment tool was used to estimate the quality of the included studies [45]. We allocated a score of 0-9 to each included article, and those with a score ≥ 6 were considered to be of high quality.

Data extraction

Data were collected using a predesigned data extraction form by two reviewers (ZJS and HL). We extracted the following data from each studies: first author’s name, year of publication, country of origin, median age, number of patients, pathological type, method of ER assessment, follow-up time, outcome endpoint, HR and 95% CI for ER-positive versus ER-negative.

In most cases, we directly extracted HR and 95% CI from primary studies. If the studies showed inadequate or unclear information, sending an email to the authors for complementary information was our first choice. If the Kaplan-Meier survival curves were available, we used the method as previously described to estimate HR and its corresponding 95% CI [40]. For multiple publications reporting the same study, only the most informative or most recent publication was included in the meta-analysis.

Statistical analysis

Pooled hazard rate (HR) with its 95% confidential interval (CI) were calculated to measure the prognostic value of ER expression among ovarian cancer patients. Heterogeneity among studies was quantified and assessed using the chi-squared-based Q and I² test and substantial heterogeneity was defined as a P-value <0.10. A random-effect model (Der Simonian and Laird method) was used if heterogeneity was observed P<0.10, otherwise, the fixed-effect model was used (Mantel-Haenszel method) [46, 47]. Potential publication bias was examined by performing funnel plots qualitatively, and estimated by Begg’s test quantitatively [48, 49]. Sensitivity analyses were employed to find potential origins of heterogeneity and to examine the influence of various exclusions on the combined HR [40]. All analyses were performed using Stata 12.0 software (StataCorp LP, College Station, TX). A P-value <0.05 was considered statistically significant.

ACKNOWLEDGMENTS

This work was supported by grants from Key Lab of Wenzhou city-Gynecological Oncology.

CONFLICTS OF INTEREST

No potential conflicts of interest were disclosed.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67:7-30.
2. Wei W, Li N, Sun Y, Li B, Xu L, Wu L. Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer. Oncotarget. 2017; 8:23862-23870. doi: 10.18632/oncotarget.13317.

3. Jönsson JM, Skovbjerg Arildsen N, Malander S, Måsbäck A, Hartman L, Nilbert M, Hedenfalk I. Sex steroid hormone receptor expression affects ovarian cancer survival. Transl Oncol. 2015; 8:424-433.

4. Liew PL, Hsu CS, Liu WM, Lee YC, Lee YC, Chen CL. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma. Int J Clin Exp Pathol. 2015; 8:85642-85649.

5. Tkalia IG, Vorobyova LI, Svintsitsky VS, Nespyradko SV, Goncharuk IV, Lukyanova NY, Chekhun VF. Clinical significance of hormonal receptor status of malignant ovarian tumors. Exp Oncol. 2014; 36:125-133.

6. Ciucci A, Zannoni GF, Travaglia D, Petritto M, Scambia G, Gallo D. Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer. Gynecol Oncol. 2014; 132:351-359.

7. Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Hegdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke B, Menon U, et al. Associations between hormone receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013; 14:853-862.

8. Hegdall EV, Christensen L, Hogdgal CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOV A' ovarian cancer study. Oncol Rep. 2014; 31:2213-2219.

9. Langdon SP, Hawkes MM, Lawrie SS, Hawkins RA, Tesdale AL, Crew AJ, Miller WR, Smyth JF. Oestrogen receptor expression and the effects of tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer. 1990; 62:213-216.

10. Langdon SP, Crew AJ, Ritchie AA, Muir M, Wakeling A, Smyth JF, Miller WR. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in vivo. Eur J Cancer. 1994; 30:682-686.

11. Bizzì A, Codegoni AM, Landoni F, Marelli G, Marsoni S, Spina AM, Torri W, Mangioni C. Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival. Cancer Res. 1988; 48:6222-6226.

12. Yang XY, Xi MR, Yang KX, Yu H. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian cancer patients. Gynecol Oncol. 2009; 113:99-104.

13. García-Velasco A, Mendiola C, Sánchez-Muñoz A, Ballestín C, Colomer R, Cortés-Funes H. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol. 2008; 10:367-371.

14. Khandakar B, Mathur SR, Kumar L, Kumar S, Datta Gupta S, Iyer VK, Kalaivan M. Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. Biomed Res Int. 2014; 2014:401245-401253.

15. de Toledo MC, Sarian LO, Sallum LF, Andrade LL, Vassallo J, de Paiva Silva GR, Pinto GA, Soares FA, Fonseca CD, Derchain SF. Analysis of the contribution of immunologically-detectable her2, steroid receptors and of the “triple-negative” tumor status disease free and overall survival of women with epithelial ovarian cancer. Acta Histochem. 2014; 116:440-447.

16. Zamagni C, Wirtz RM, De Iaco P, Rosati M, Veltrup E, Rosati F, Capizzi E, Cacciari N, Alboni C, Bernardi A, Massari F, Quercia S, D’Errico Grigioni A, et al. Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. Endocr Relat Cancer. 2009; 16:1241-1249.

17. Burges A, Brüning A, Dannenmann C, Blankenstein T, Jeschke U, Shabani N, Friese K, Mylonas I. Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet. 2010; 281:511-517.

18. Halon A, Matarena V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P, Spaczynski M, Zabel M, Dietel M, Lage H, Surowiak P. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res. 2011; 17:511-518.

19. van Kruchten M, van der Marel P, de Munck L, Hollema H, Arts H, Timmer-Bosscha H, de Vries E, Hoppers G, Reyners A. Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol Oncol. 2015; 138:634-639.

20. Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, Im DD, Rosenshein NB, Roman LD, Sood AK. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol Oncol. 2014; 133:473-479.

21. Battista MJ, Mantai N, Sicking I, Cotarelo C, Weyer V, Lebrecht A, Solbach C, Schmidt M, Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study. Oncol Rep. 2014; 31:2213-2219.

22. Lenhard M, Tereza L, Heublein S, Ditsch N, Himsl I, Mayr D, Friese K, Jeschke U. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer. 2012; 12:553-562.

23. Fujiwara S, Terai Y, Kawaguchi H, Takai M, Yoo S, Tanaka Y, Tanaka T, Tsumoto S, Sasaki H, Kanemura M, Tanabe A, Yamashita Y, Ohmichi M. GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer. J Ovarian Res. 2012; 5:35-44.
24. Aust S, Bachmayer-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C, Chekerov R, Sehouli J, Mahner S, Van Gorp T, Vergote I, Speiser P, Horvat R, et al. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer - a study of the OVCAD consortium. Mol Cancer. 2012; 11:69-78.

25. Schlumberreth MP, Xie SS, Shipley GL, Urbauer DL, Broaddas RR. Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum. Mod Pathol. 2011; 24:453-462.

26. Scambia G, Benedetti-Panici P, Ferrandina G, Distefano M, Salerno G, Romanini ME, Fagotti A, Mancuso S. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer. 1995; 72:361-366.

27. Kieback DG, McCamant SK, Press MF, Atkinson EN, Gallagher HS, Edwards CL, Hajek RA, Jones LA. Improved prediction of survival in advanced adenocarcinoma of the ovary by immunochemicalanalysis and the composition adjusted receptor level of the estrogen receptor. Cancer Res. 1993; 53:5188-5192.

28. Geisler JP, Wiemann MC, Miller GA, Geisler HE. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIC serous cystadenocarcinoma of the ovary. Gynecol Oncol. 1996; 60:424-427.

29. Athanassiadou P, Sakellariou V, Petrakakou E, Athanassiades P, Zerva C, Liossi A, Michalas S. Cathepsin D immunoreactivity in ovarian cancer: correlation with prognostic factors. Pathol Oncol Res. 1998; 4:103-107.

30. Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol. 2005; 96:671-677.

31. De Sousa Damião R, Fujiyama Oshima CT, Stávalle JN, Gonçalves WJ. Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. Oncol Rep. 2007; 18:25-32.

32. Buchynska LG, Iurchenko NP, Grinkevych VM, Nesina IP, Chekhun SV, Svintsitsky VS. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers. Exp Oncol. 2009; 31:48-51.

33. Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, Prossnitz ER, Verschraegen CF. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol. 2009; 114:480-485.

34. Darb-Esfahani S, Wirtz RM, Sinn BV, Budczies J, Noske A, Weichert W, Faggard A, Scharff S, Sehouli J, Öskay-Ozcelik G, Zamagni C, De Iaco P, Martoni A, et al. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. Endocr Relat Cancer. 2009; 16:1229-1239.

35. Liu JF, Hirsch MS, Lee H, Matulonis UA. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol. 2009; 115:401-406.

36. Alonso L, Gallego E, González-FJ, Sánchez-Muñoz A, Torres E, Pajares BI, Leeflang S, Bahá C. Gonadotropin and steroid receptors as prognostic factors in advanced ovarian cancer: a retrospective study. Clin Transl Oncol. 2009; 11:748-752.

37. Liu N, Wang X, Sheng X. The clinicopathological characteristics of ‘‘triple-negative’’ epithelial ovarian cancer. J Clin Pathol. 2010; 63:240-243.

38. De Stefano I, Zannoni GF, Prisco MG, Fagotti A, Tortorella L, Vizzieri G, Menzaglia L, Scambia G, Gallo D. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecol Oncol. 2011; 122:573-579.

39. Kolokova Z, Casslén V, Henic E, Ahmadi S, Ehinger A, Jirström K, Casslén B. The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer. J Ovarian Res. 2012; 5:9-19.

40. Zhu H, Luo H, Zhu X, Hu X, Zheng L, Zhu X. Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis. Oncotarget. 2017; 8:1628-1640. doi: 10.18632/oncotarget.13703.

41. Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2013; 23:25-33.

42. Brown D, Shao S, Jatoi I, Shriver CD, Zhu K. Trends in use of contralateral prophylactic mastectomy by racial/ethnic group and ER/PR status among patients with breast cancer: a SEER population-based study. Cancer Epidemiol. 2016; 42:24-31.

43. Han SJ, Guo QQ, Wang T, Wang YX, Zhang YX, Liu F, Luo YX, Zhang J, Wang YL, Yan YX, Peng XX, Yan YX, Ling R, He Y. Prognostic significance of interactions between ER alpha and ER beta and lymph node status in breast cancer cases. Asian Pac J Cancer Prev. 2013; 14:6081-6084.

44. Chuffa LG, Lupi-Júnior LA, Costa AB, Amorim JP, Seiva FR. The role of sex hormones and steroid receptors on female reproductive cancers. Steroids. 2017; 118:93-108.

45. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25:603-605.

46. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-188.

47. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22:719-748.

48. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629-634.

49. Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2013; 23:25-33.

50. Brown D, Shao S, Jatoi I, Shriver CD, Zhu K. Trends in use of contralateral prophylactic mastectomy by racial/ethnic group and ER/PR status among patients with breast cancer: a SEER population-based study. Cancer Epidemiol. 2016; 42:24-31.